Hypertension in obesity: Is leptin the culprit?

Trends in Neurosciences

Volumn 36, Issue 2, 2013, Pages 121-132

  Simonds, Stephanie E ^a   Cowley, Michael A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Dorsomedial hypothalamus; Hypertension; Hypothalamus; Leptin; Obesity; Sympathetic nerve activity

Indexed keywords

INSULIN RECEPTOR; LEPTIN; LEPTIN RECEPTOR; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR;

ABDOMINAL PRESSURE; ADRENERGIC SYSTEM; BLOOD VOLUME; BORDERLINE HYPERTENSION; BROWN ADIPOSE TISSUE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CRANIAL NERVE; ENERGY CONSUMPTION; ENERGY EXPENDITURE; FLUID BALANCE; GLOMERULUS FILTRATION; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTESTINE INNERVATION; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE PRESSURE; LIPID STORAGE; MOTONEURON NUCLEUS; NATRIURESIS; NERVE CELL; NERVE CONDUCTION; OBESITY; PARASYMPATHETIC INNERVATION; PARASYMPATHETIC NERVE; PARASYMPATHETIC TONE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RENAL ARTERY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM ABSORPTION; STRIA TERMINALIS; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE; THERMOGENESIS; TISSUE PRESSURE; WEIGHT GAIN; WEIGHT REDUCTION;

BRAIN; ENERGY METABOLISM; HUMANS; HYPERTENSION; LEPTIN; OBESITY;

EID: 84873163621     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2013.01.004     Document Type: Review

References (135)

1. Finucane M.M., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377:557-567.
2. McCullough P.A. Coronary artery disease. Clin. J. Am. Soc. Nephrol. 2007, 2:611-616.
3. Roger V.L., et al. Heart disease and stroke statistics: 2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
4. Roger V.L., et al. Heart disease and stroke statistics: 2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
5. O'Donnell C.J., et al. Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation 1997, 95:1132-1137.
6. Poirier P., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113:898-918.
7. Maffei M., et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med. 1995, 1:1155-1161.
8. Heymsfield S.B., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282:1568-1575.
9. Haynes W.G., et al. Receptor-mediated regional sympathetic nerve activation by leptin. J. Clin. Invest. 1997, 100:270-278.
10. Vaz M., et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997, 96:3423-3429.
11. Rahmouni K., et al. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005, 54:2012-2018.
12. Martin U. Hypertension guidelines: thresholds, targets, and teratogenicity. Br. J. Gen. Pract. 2008, 58:585.
13. Giles T.D., et al. Expanding the definition and classification of hypertension. J. Clin. Hypertens. 2005, 7:505-512.
14. Chobanian A.V., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
15. Lambert E., et al. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension 2010, 56:351-358.
16. Mullins L.J., et al. Hypertension, kidney, and transgenics: a fresh perspective. Physiol. Rev. 2006, 86:709-746.
17. Malpas S.C. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol. Rev. 2010, 90:513-557.
18. Page I.H. A method for producing persistent hypertension by cellophane. Science 1939, 89:273-274.
19. Badyal D.K., et al. Animal models of hypertension and effect of drugs. Indian J. Pharmacol. 2003, 35:349-362.
20. Marchal A.L., et al. [Arterial hypertension caused by extrinsic compression of the renal artery of tumor origin in a child]. Pediatrie 1986, 41:475-480.
21. Albayrak R., et al. Arterial hypertension due to primary huge hepatic hydatid cyst: a case report. Turk. J. Med. Sci. 2006, 36:129-131.
22. Barger A.C. The Goldblatt memorial lecture. Part I: Experimental renovascular hyptertension. Hypertension 1979, 1:447-455.
23. Houssay B.A., Fasicolo J.C. Demostración del mecanismo humoral de la hipertensión nefrógena. Bol. Acad. Med. Buenos Aires 1937, 18:342-344.
24. Houssay B.A., Taquini A.C. Acción vasoconstrictora de la sangre venosa del riñón isquemiado. Rev. Soc. Argent. Biol. 1938, 14:5-14.
25. Palatini P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol. Dial. Transplant. 2012, 27:1708-1714.
26. Palatini P., et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int. 2006, 70:578-584.
27. Arone L.J., et al. Autonomic nervous system activity in weight gain and weight loss. Am. J. Physiol. 1995, 269:R222-R225.
28. Julius S., et al. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971, 44:413-418.
29. Bernard C. Influence de grand sympathetique sur la sensibilitie et sur la calorification. C. R. Soc. Biol. Paris 1851, 3:163-164.
30. Sly J.D., et al. Identification of neural projections from the forebrain to the kidney, using the virus pseudorabies. J. Auton. Nerv. Syst. 1999, 77:73-82.
31. Ulrich-Lai Y.M., Herman J.P. Neural regulation of endocrine and autonomic stress responses. Nat. Rev. Neurosci. 2009, 10:397-409.
32. Bachman E.S., et al. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002, 297:843-845.
33. Commins S.P., et al. Norepinephrine is required for leptin effects on gene expression in brown and white adipose tissue. Endocrinology 1999, 140:4772-4778.
34. Bartness T.J., et al. Sympathetic and sensory innervation of brown adipose tissue. Int. J. Obes. 2010, 34(Suppl. 1):S36-S42.
35. Hamilton J.M., et al. Effects of norepinephrine and denervation on brown adipose tissue in Syrian hamsters. Am. J. Physiol. 1989, 257:R396-R404.
36. Himms-Hagen J., et al. Sympathetic and sensory nerves in control of growth of brown adipose tissue: effects of denervation and of capsaicin. Neurochem. Int. 1990, 17:271-279.
37. Ueta C.B., et al. beta(1) Adrenergic receptor is key to cold- and diet-induced thermogenesis in mice. J. Endocrinol. 2012, 214:359-365.
38. Fan W., et al. Regulation of thermogenesis by the central melanocortin system. Peptides 2005, 26:1800-1813.
39. Simonds S.E., et al. Leptin increasing sympathetic nerve outflow in obesity: a cure for obesity or a potential contributor to metabolic syndrome?. Adipocyte 2012, 1:177-181.
40. Bouillaud F., et al. Increased level of mRNA for the uncoupling protein in brown adipose tissue of rats during thermogenesis induced by cold exposure or norepinephrine infusion. J. Biol. Chem. 1984, 259:11583-11586.
41. Clarke S.D., et al. Post-prandial heat production in skeletal muscle is associated with altered mitochondrial function and altered futile calcium cycling. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 303:R1071-R1079.
42. Cannon B. The effects of progressive sympathectomy on blood pressure. Am. J. Physiol. 1931, 97:592-596.
43. Kline R.L. Renal nerves and experimental hypertension: evidence and controversy. Can. J. Physiol. Pharmacol. 1987, 65:1540-1547.
44. Kassab S., et al. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995, 25:893-897.
45. Smithwick R.H., Thompson J.E. Splanchnicectomy for essential hypertension; results in 1,266 cases. JAMA 1953, 152:1501-1504.
46. Schlaich M.P., et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med. 2009, 361:932-934.
47. Krum H., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
48. Ferrier C., et al. Elevated total body noradrenaline spillover in normotensive members of hypertensive families. Clin. Sci. 1993, 84:225-230.
49. Lambert G.W., et al. Cerebral noradrenaline spillover and its relation to muscle sympathetic nervous activity in healthy human subjects. J. Auton. Nerv. Syst. 1997, 64:57-64.
50. Grima P., et al. Ultrasound-assessed perirenal fat is related to increased ophthalmic artery resistance index in HIV-1 patients. Cardiovasc. Ultrasound 2010, 8:24.
51. Hall J.E., et al. Mechanisms of hypertension and kidney disease in obesity. Ann. N. Y. Acad. Sci. 1999, 892:91-107.
52. Sugerman H., et al. Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. J. Intern. Med. 1997, 241:71-79.
53. Rosito G.A., et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008, 117:605-613.
54. Larsson B., et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br. Med. J. 1984, 288:1401-1404.
55. Mark A.L., et al. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J. Hypertens. 1999, 17:1949-1953.
56. Silvani A., et al. Sleep modulates hypertension in leptin-deficient obese mice. Hypertension 2009, 53:251-525.
57. Van Vliet B.N., et al. Reduced parasympathetic control of heart rate in obese dogs. Am. J. Physiol. 1995, 269:H629-H637.
58. Gautron L., et al. Identifying the efferent projections of leptin-responsive neurons in the dorsomedial hypothalamus using a novel conditional tracing approach. J. Comp. Neurol. 2010, 518:2090-2108.
59. Kishi T., et al. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J. Comp. Neurol. 2003, 457:213-235.
60. Liu H., et al. Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. J. Neurosci. 2003, 23:7143-7154.
61. Greenfield J.R., et al. Modulation of blood pressure by central melanocortinergic pathways. N. Engl. J. Med. 2009, 360:44-52.
62. Haynes W.G., et al. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999, 33:542-547.
63. Tallam L.S., et al. Melanocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia. Hypertension 2005, 46:326-332.
64. Rossi J., et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab. 2011, 13:195-204.
65. Rumantir M.S., et al. Neural mechanisms in human obesity-related hypertension. J. Hypertens. 1999, 17:1125-1133.
66. Bray G.A., et al. Experimental obesity: a homeostatic failure due to defective nutrient stimulation of the sympathetic nervous system. Vitam. Horm. 1989, 45:1-125.
67. Esler M., et al. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006, 48:787-796.
68. Enriori P.J., et al. Leptin action in the dorsomedial hypothalamus increases sympathetic tone to brown adipose tissue in spite of systemic leptin resistance. J. Neurosci. 2011, 31:12189-12197.
69. Grassi G., et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998, 97:2037-2042.
70. Straznicky N.E., et al. The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J. Clin. Endocrinol. Metab. 2011, 96:E503-E508.
71. Lambert G.W., et al. Sympathetic nervous activation in obesity and the metabolic syndrome: causes, consequences and therapeutic implications. Pharmacol. Ther. 2010, 126:159-172.
72. Zhang Y., et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
73. Halaas J.L., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543-546.
74. Shek E.W., et al. Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31:409-414.
75. Ribeiro A.C., et al. Contrasting effects of leptin on food anticipatory and total locomotor activity. PLoS ONE 2011, 6:e23364.
76. Harris R.B., et al. A leptin dose-response study in obese (ob/ob) and lean (+/?) mice. Endocrinology 1998, 139:8-19.
77. Commins S.P., et al. Central leptin regulates the UCP1 and ob genes in brown and white adipose tissue via different beta-adrenoceptor subtypes. J. Biol. Chem. 2000, 275:33059-33067.
78. Ozata M., et al. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J. Clin. Endocrinol. Metab. 1999, 84:3686-3695.
79. Munzberg H., et al. Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 2004, 145:4880-4889.
80. Morrison S.F., et al. Central control of thermogenesis in mammals. Exp. Physiol. 2008, 93:773-797.
81. Rahmouni K., et al. Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension 2002, 39:486-490.
82. Eikelis N., et al. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003, 41:1072-1079.
83. Shankar A., Xiao J. Positive relationship between plasma leptin level and hypertension. Hypertension 2010, 56:623-628.
84. Scott M.M., et al. Leptin targets in the mouse brain. J. Comp. Neurol. 2009, 514:518-532.
85. Kong D., et al. GABAergic RIP-Cre neurons in the arcuate nucleus selectively regulate energy expenditure. Cell 2012, 151:645-657.
86. Cowley M.A., et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001, 411:480-484.
87. Berglund E.D., et al. Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J. Clin. Invest. 2012, 122:1000-1009.
88. Cone R.D. Anatomy and regulation of the central melanocortin system. Nat. Neurosci. 2005, 8:571-578.
89. Rahmouni K., et al. Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin. J. Neurosci. 2003, 23:5998-6004.
90. Kievit P., et al. Chronic treatment with a melanocortin 4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 2012, 10.2337/db12-0598.
91. Spanswick D., et al. Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels. Nature 1997, 390:521-525.
92. Vong L., et al. Leptin action on GABAergic neurons prevents obesity and reduces inhibitory tone to POMC neurons. Neuron 2011, 71:142-154.
93. Patel H.R., et al. Neuropeptide Y deficiency attenuates responses to fasting and high-fat diet in obesity-prone mice. Diabetes 2006, 55:3091-3098.
94. Hollopeter G., et al. Role of neuropeptide Y in diet-, chemical- and genetic-induced obesity of mice. Int. J. Obes. Relat. Metab. Disord. 1998, 22:506-512.
95. Erickson J.C., et al. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996, 274:1704-1707.
96. Herzog H., Neuropeptide Y. and energy homeostasis: insights from Y receptor knockout models. Eur. J. Pharmacol. 2003, 480:21-29.
97. Enriori P.J., et al. Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. Cell Metab. 2007, 5:181-194.
98. Considine R.V., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996, 334:292-295.
99. Morgan D.A., et al. Mechanisms mediating renal sympathetic activation to leptin in obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:R1730-R1736.
100. Aizawa-Abe M., et al. Pathophysiological role of leptin in obesity-related hypertension. J. Clin. Invest. 2000, 105:1243-1252.
101. Masuo K., et al. Leptin-receptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic nerve activation in a Caucasian male population. Hypertens. Res. 2008, 31:1093-1100.
102. Silva A.A., et al. Does obesity induce resistance to the long-term cardiovascular and metabolic actions of melanocortin 3/4 receptor activation?. Hypertension 2006, 47:259-264.
103. Dubinion J.H., et al. Enhanced blood pressure and appetite responses to chronic central melanocortin-3/4 receptor blockade in dietary-induced obesity. J. Hypertens. 2010, 28:1466-1470.
104. da Silva A.A., et al. Role of hypothalamic melanocortin 3/4-receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension 2004, 43:1312-1317.
105. Sayk F., et al. Sympathetic function in human carriers of melanocortin-4 receptor gene mutations. J. Clin. Endocrinol. Metab. 2010, 95:1998-2002.
106. do Carmo J.M., et al. Control of blood pressure, appetite, and glucose by leptin in mice lacking leptin receptors in proopiomelanocortin neurons. Hypertension 2011, 57:918-926.
107. Harlan S.M., et al. Ablation of the leptin receptor in the hypothalamic arcuate nucleus abrogates leptin-induced sympathetic activation. Circ. Res. 2011, 108:808-812.
108. Marsh A.J., et al. Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and dorsomedial hypothalamus. Hypertension 2003, 42:488-493.
109. Dampney R.A., et al. Long-term regulation of arterial blood pressure by hypothalamic nuclei: some critical questions. Clin. Exp. Pharmacol. Physiol. 2005, 32:419-425.
110. Elmquist J.K., et al. Leptin activates distinct projections from the dorsomedial and ventromedial hypothalamic nuclei. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:741-746.
111. Horiuchi J., et al. Descending vasomotor pathways from the dorsomedial hypothalamic nucleus: role of medullary raphe and RVLM. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287:R824-R832.
112. Fontes M.A., et al. Descending pathways mediating cardiovascular response from dorsomedial hypothalamic nucleus. Am. J. Physiol. Heart Circ. Physiol. 2001, 280:H2891-H2901.
113. Horiuchi J., et al. Differential control of cardiac and sympathetic vasomotor activity from the dorsomedial hypothalamus. Clin. Exp. Pharmacol. Physiol. 2006, 33:1265-1268.
114. Zhang Y., et al. Leptin-receptor-expressing neurons in the dorsomedial hypothalamus and median preoptic area regulate sympathetic brown adipose tissue circuits. J. Neurosci. 2011, 31:1873-1884.
115. Cao W.H., Morrison S.F. Disinhibition of rostral raphe pallidus neurons increases cardiac sympathetic nerve activity and heart rate. Brain Res. 2003, 980:1-10.
116. Concha J., Norris B. Studies on renal vasomotion. Br. J. Pharmacol. 1968, 34:277-290.
117. Lee S., et al. Laser-capture microdissection and transcriptional profiling of the dorsomedial nucleus of the hypothalamus. J. Comp. Neurol. 2012, 520:3617-3632.
118. Grill H.J., et al. Evidence that the caudal brainstem is a target for the inhibitory effect of leptin on food intake. Endocrinology 2002, 143:239-246.
119. Hayes M.R., et al. Endogenous leptin signaling in the caudal nucleus tractus solitarius and area postrema is required for energy balance regulation. Cell Metab. 2010, 11:77-83.
120. Mark A.L., et al. Leptin signaling in the nucleus tractus solitarii increases sympathetic nerve activity to the kidney. Hypertension 2009, 53:375-380.
121. Matsumura K., et al. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002, 40:694-699.
122. Lambert E., et al. Ghrelin modulates sympathetic nervous system activity and stress response in lean and overweight men. Hypertension 2011, 58:43-50.
123. Cassaglia P.A., et al. Insulin acts in the arcuate nucleus to increase lumbar sympathetic nerve activity and baroreflex function in rats. J. Physiol. 2011, 589:1643-1662.
124. Ward K.R., et al. Sympathetic response to insulin is mediated by melanocortin 3/4 receptors in the hypothalamic paraventricular nucleus. Hypertension 2011, 57:435-441.
125. Morgan D.A., Rahmouni K. Differential effects of insulin on sympathetic nerve activity in agouti obese mice. J. Hypertens. 2010, 28:1913-1919.
126. Modan M., et al. Hyperinsulinemia. a link between hypertension obesity and glucose intolerance. J. Clin. Invest. 1985, 75:809-817.
127. Ma X., et al. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J. Neurosci. 2007, 27:7125-7129.
128. Yamamoto H., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 2002, 110:43-52.
129. Lockie S.H., et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 2012, 61:2753-2762.
130. Pelleymounter M.A., et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995, 269:540-543.
131. Tartaglia L.A., et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995, 83:1263-1271.
132. Collins S., et al. Role of leptin in fat regulation. Nature 1996, 380:677.
133. Berthoud H.R., et al. Vagaries of adipose tissue innervation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291:R1240-R1242.
134. Giordano A., et al. White adipose tissue lacks significant vagal innervation and immunohistochemical evidence of parasympathetic innervation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291:R1243-R1255.
135. Kreier F., et al. Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology 2006, 147:1140-1147.